Current evidence of any of the following:\r\n* Known gastrointestinal disorder affecting absorption of oral medications\r\n* Active uncontrolled infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis) \r\n* Uncontrolled hypertension\r\n* Any current condition that in the opinion of the investigator, would preclude participation in this study
Patients with a known history of infection with hepatitis B or hepatitis C virus (active, previously treated, or both) will not be eligible due to the increased risk of hepatotoxicity and viral reactivation associated with systemic chemotherapy
Patients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis
Active or chronic viral hepatitis B or C infection
Known human immunodeficiency virus or active hepatitis C viral infection
Active hepatitis B viral infection (defined as HBsAg+).
Patients with known (testing is not part of the protocol) active hepatic disease (i.e., hepatitis B or C) due to risk of drug interactions with anti-viral therapy
Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection (hepatitis B carriers with normal liver function tests [LFTs] and undetectable viral loads are allowed)
Active infection or ongoing antiviral medication for viral infections including hepatitis B, hepatitis C, or human immunodeficiency virus (HIV); screening for chronic conditions is not required; HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with selumetinib or osimertinib
Active and clinically significant bacterial, fungal or viral infection\r\n* Known infections with hepatitis B (HBV) or hepatitis C (HCV)\r\n* Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness not controlled (with undetectable viral load) on highly active antiretroviral therapy (HAART) therapy; patients on HAART with undetectable viral loads may be eligible per principal investigator (PI) judgment
Known human immunodeficiency virus or active hepatitis B or C viral infection
Patients with active viral hepatitis.
Has active human immunodeficiency virus infection that is uncontrolled (increasing plasma HIV RNA viral load) with medication, or has an active hepatitis B or C infection
Active or chronic viral hepatitis B or C infection Exclusions Related to Ocular Disease
Patients with other viral infections are ineligible:\r\n* Known to have acute or chronic active hepatitis B or hepatitis C infection\r\n* Known to have human immunodeficiency virus (HIV) infection\r\n* Prior therapy with viral-based tumor vaccine\r\n* Received live vaccine within  days prior to enrollment
Subjects with known HIV or active viral hepatitis
Chronic active or active viral hepatitis A, B, or C infection
Active systemic illness (infection including viral illnesses such as hepatitis and human immunodeficiency virus [HIV])
Patients known to be HIV positive or have active viral hepatitis.
Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for - hours
Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)
Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)
Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for - hours prior to study day , unless fever is thought to be secondary to the underlying hematologic disease
Known active acute or chronic infection including urinary tract infection, human immunodeficiency virus (HIV) or viral hepatitis
Active hepatitis, including but not limited to viral and drug-induced
Active uncontrolled infection; presence of latent or medication-controlled human immunodeficiency virus (HIV) and/or viral hepatitis is allowed
Patients with hepatitis B and/or hepatitis C infection are excluded if they are on any of the following viral suppressive agents: boceprevir (Victrelis), ribavirin (Rebetol, Ribatab, Ribasphere), telaprevir (Incivek)\r\n* Note: patients with active hepatitis B infection must be on treatment with viral suppressive therapies; these agents may include the following: adefovir (Hepsera), entecavir (Baraclude), lamivudine (Epivir-HBV), telbivudine (Tyzeka), and/or tenofovir (Viread)
Known active human immunodeficiency virus (HIV), hepatitis B or C or infection; exception for patients with hepatitis B on antivirals and low viral load, to be determined at the discretion of the investigator
Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis.
Uncontrolled infection, defined as an infection which has not resolved spontaneously or does not show evidence of significant resolution after initiating appropriate therapy, excluding chronic asymptomatic viral infections (e.g., human papillomavirus [HPV], BK virus, hepatitis C virus [HCV], etc.)
Active or symptomatic infection including human immunodeficiency virus (HIV), viral hepatitis or chronic liver disease
History of immunodeficiency including seropositivity for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or any active systemic viral infection requiring therapy (e.g., hepatitis B or C)
Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials, and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. known chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for  hours; patients with fever thought to be likely secondary to leukemia are eligible
Known acute viral hepatitis
Active viral hepatitis.
Participant has an active systemic fungal and/or known viral infection (for example, human immunodeficiency virus antibodies, hepatitis B surface antigen or hepatitis C antibodies)
Other viral infections:\r\n* Known to have acute or chronic active hepatitis B or hepatitis C infection\r\n* Known to have human immunodeficiency virus (HIV) infection\r\n* Prior therapy with viral-based tumor vaccine\r\n* Received live vaccine within  days prior to enrollment
Other viral infections\r\n* Known to have acute or chronic active hepatitis B or hepatitis C infection\r\n* Known to have human immunodeficiency virus (HIV) infection\r\n* Prior therapy with viral-based tumor vaccine\r\n* Received live vaccine within  days prior to enrollment
Patients with chronic viral illnesses such as human immunodeficiency virus (HIV)-positivity and active hepatitis B or C are ineligible
DONOR: Evidence of active infection or viral hepatitis
Patients with human immunodeficiency virus (HIV) or hepatitis, or known active cytomegalovirus (CMV), EpsteinBarr virus (EBV) or any other viral illness requiring treatment are ineligible
DONOR: Evidence of active infection or viral hepatitis
Current infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C. Patients will have serologic testing performed during screening for HIV and hepatitis B and C. Any serologic results suggestive of an ongoing viral infection will be further investigated as necessary to clarify the patients status
Patients with human immunodeficiency virus (HIV) disease or active viral hepatitis
Relevant diseases or clinical situations which may increase patient's risk: History of cardiac disease. Moderate breathing difficulties or oxygen requirement Active uncontrolled infection. Unhealed wound or presence of any external drainage. Chronically active viral hepatitis. Immunocompromised patients, including those known to be infected by human immunodeficiency virus (HIV). Known muscular disease or functional alteration
Active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease.
Known HIV or hepatitis B or C viral infection
Active viral hepatitis or active human immunodeficiency virus infection
Patients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis (B or C)
Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for  hours; patients with fever thought to be likely secondary to leukemia are eligible
Confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis
Active/uncontrolled viral hepatitis
Serious, intercurrent illness including, but not limited to, clinically relevant active infection, known active hepatitis B or C viral infection, known human immunodeficiency virus (HIV) infection, uncontrolled diabetes mellitus, or serious co-morbid medical conditions such as chronic restrictive pulmonary disease, and cirrhosis
Active viral hepatitis
Serious, intercurrent illness including, but not limited to, clinically relevant active infection, known active hepatitis B or C viral infection, known human immunodeficiency virus (HIV) infection, uncontrolled diabetes mellitus, or serious co-morbid medical conditions such as chronic restrictive pulmonary disease, and cirrhosis
A known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis
Known active viral infection\r\n* Note: viral hepatitis testing is required at screening for all patients
Active or chronic systemic infection, including viral hepatitis, human immunodeficiency virus (HIV), mycobacteria, tuberculosis (TB), or other opportunistic infections
Active or symptomatic viral hepatitis
Severe active viral infection, especially hepatitis B.
Presence of an active acute or chronic infection, including urinary tract infection, human immunodeficiency virus (HIV) or viral hepatitis HIV patients are excluded based on immunosuppression which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections; if clinically indicate HIV/viral hepatitis testing will be performed to confirm status
Evidence of infection with human immunodeficiency virus (HIV) or viral hepatitis
Clinically significant active infection (e.g. tuberculosis, viral hepatitis, HIV)
Known acute viral hepatitis
Patients with active viral hepatitis
Patients with previously known infection with human immunodeficiency virus (HIV) or active viral hepatitis are ineligible; (diagnostic testing for these infections will be done only if clinically indicated)
Known HIV or active hepatitis B or C viral infection.
Active viral hepatitis
Patients with known human immunodeficiency virus (HIV), hepatitis B or C (however, if patients have previously been treated for hepatitis B or C and have undetectable viral loads, they can be considered eligible for trial)
Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for  hours; patients with fever thought to be likely secondary to leukemia are eligible
Active hepatitis B or C viral infection
Participants who are known to have active hepatitis A, B, or C viral infection may not participate in this study; active disease is defined as participants with a known viral hepatitis whose liver function tests are elevated beyond the criteria indicated
Known or active HIV, viral hepatitis B or C
Have an active systemic fungal and/or known viral infection (for example, human immunodeficiency virus antibodies, hepatitis B surface antigen, or hepatitis C antibodies)
DONOR: Evidence of active infection or viral hepatitis
Active or uncontrolled clinically serious infection. (Participants with chronic viral hepatitis are eligible.)
Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis.
Known immunosuppressive disease, autoimmune condition, and/or chronic viral infection (eg, human immunodeficiency virus [HIV], hepatitis)
Known HIV or active hepatitis B or C viral infection
Active systemic illness (infection including viral illnesses such as hepatitis and human immunodeficiency virus [HIV])
Active viral hepatitis or symptomatic human immunodeficiency virus (HIV) infection
Patients who are immunosuppressed (including known HIV infection), have a serious active infection at the time of treatment, have interstitial lung disease/pneumonitis, or have any serious underlying medical condition that would impair the ability of the patient to receive protocol treatment. Patients with controlled hepatitis C, in the investigator's opinion, are allowed. Patients with known hepatitis B must be HBeAg and HB viral DNA negative for enrollment. Note that, because of the high prevalence, all patients in the Asia-Pacific region (except Australia, New Zealand, and Japan) must be tested and, if HBsAg positive, must be HBeAg and HB viral DNA negative for enrollment.
